研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

人类癌症中 snoRNA 的药物基因组学和免疫景观。

The pharmacogenomic and immune landscape of snoRNAs in human cancers.

发表日期:2024 Oct 17
作者: Runhao Wang, Chengxuan Chen, Yuan Liu, Mei Luo, Jingwen Yang, Yamei Chen, Lifei Ma, Liuqing Yang, Chunru Lin, Lixia Diao, Leng Han
来源: CANCER LETTERS

摘要:

小核仁 RNA (snoRNA) 是一类非编码 RNA,主要因其在其他 RNA 化学修饰中的作用而闻名。最近的研究表明,snoRNA 可能在靶向治疗和免疫治疗等抗癌治疗中发挥更广泛的作用。尽管有这些见解,snoRNA 与药物反应和免疫治疗结果关联的全面景观仍未得到探索。在这项研究中,我们使用 VAEN 和 CancerRxTissue 的数据分别确定了 snoRNA 与药物反应之间的 79,448 和 75,185 关联。此外,我们发现 snoRNA 与免疫检查点基因之间有 29,199 个关联,以及 snoRNA 与免疫细胞浸润之间有 47,194 个关联。 16 个 snoRNA 与免疫治疗客观缓解率 (ORR) 显着相关,92 个 snoRNA 在高 ORR 和低 ORR 的癌症之间表现出显着差异表达。此外,我们还发现了 17 种 snoRNA 在免疫相关不良事件 (irAE) 报告优势比 (ROR) 高和低的癌症类型之间表达显着差异。几种 snoRNA,例如 SNORD92 和 SNORD83B,可能代表有希望的生物标志物或需要进一步研究的治疗靶点。为了促进进一步的研究,我们开发了一个用户友好的门户网站,SnoRNA 的药物基因组学和免疫景观(PISNO,https://hanlaboratory.com/PISNO/),使研究人员能够可视化、浏览和下载多维数据。这项研究强调了 snoRNA 作为生物标志物或治疗靶点的潜力,为更有效和个性化的抗癌治疗铺平了道路。版权所有 © 2024。由 Elsevier B.V. 出版。
Small nucleolar RNAs (snoRNAs) are a class of non-coding RNAs primarily known for their role in the chemical modification of other RNAs. Recent studies suggested that snoRNAs may play a broader role in anti-cancer treatments such as targeted therapies and immunotherapies. Despite these insights, the comprehensive landscape of snoRNA associations with drug response and immunotherapy outcomes remains unexplored. In this study, we identified 79,448 and 75,185 associations between snoRNAs and drug response using data from VAEN and CancerRxTissue, respectively. Additionally, we discovered 29,199 associations between snoRNAs and immune checkpoint genes and 47,194 associations between snoRNAs and immune cell infiltrations. Sixteen snoRNAs were significantly correlated with immunotherapy objective response rate (ORR), and 92 snoRNAs showed significantly differential expression between cancers with high and low ORR. Furthermore, we identified 17 snoRNAs with significantly differential expression between cancer types with high and low immune-related adverse event (irAE) reporting odds ratio (ROR). Several snoRNAs, such as SNORD92, and SNORD83B, may represent promising biomarkers or therapeutic targets that needs further investigation. To facilitate further research, we developed a user-friendly portal, Pharmacogenomic and Immune Landscape of SnoRNA (PISNO, https://hanlaboratory.com/PISNO/), enabling researchers to visualize, browse, and download multi-dimensional data. This study highlights the potential of snoRNAs as biomarkers or therapeutic targets, paving the way for more effective and personalized anti-cancer treatments.Copyright © 2024. Published by Elsevier B.V.